To learn more about the trial’s primary analyses and follow-up data extending up to 75 months, please click on the resource to download the KEYNOTE-522 clinical data presentation.

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.¹

Refer to the Summary of Product Characteristics and Risk Minimisation Materials available on the emc website before prescribing, in order to help reduce the risk associated with KEYTRUDA.